This is a descriptive pilot study on a ready-constituted biobank (outside the Jardé Law). It is an ancillary study to the "GrossPath" cohort (RCB ID number: 2014-A01120-47). Pregnancy generates an increased risk of thrombosis, and placenta-mediated diseases constitute a risk factor for cardiovascular pathologies responsible for significant maternal-fetal morbidity and mortality. Understanding and exploring the cellular and molecular mechanisms of dysfunctions of the vascular-placental interface could provide arguments to understand the systemic vascular risk, characterize it and finally detect it on the basis of new markers, thus opening the way for targeted preventive management to reinforce the general principles of precision medicine. Netosis is a process of activation of neutrophils, which then generate filaments containing DNA, enzymes and extracellular histones. Netosis occurs in pregnancy and is increased in vascular-placental complications. It can be studied by measuring circulating histones, particularly the citrullinated histone H3. Levels of this modified histone H3, as well as those of two other modifications, have recently been shown to increase during pregnancy. These levels have also been shown to be even greater in pregnancy complications. The aim of this study is to complete this mapping in order to obtain a precise signature for all post-translational histone modifications in normal pregnancies and pregnancies complicated by pre-eclampsia from the "GrossPath" cohort in order to propose new circulating biomarkers for placental vascular pathologies. The post-translational histone modification profiles (mapping) of pregnant women with normal pregnancies will be compared with those developing pre-eclampsia.
Study Type
OBSERVATIONAL
Enrollment
28
During the "GrossHist" study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company \[Bouvier and Fortier et al. 2021\]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4).
Nîmes University Hospital
Nîmes, Gard, France
Presence of methylation in histone H2A in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of methylation in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H2B in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of methylation in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H3 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of methylation in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H4 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of methylation in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H2A in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of acetylation in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H2B in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of acetylation in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H3 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of acetylation in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H4 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of acetylation in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H2A in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H2B in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H3 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H4 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of phosphorylation in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H2A in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H2B in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H3 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H4 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of ubiquitination in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H2A in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of citrullination in histone H2A and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H2B in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of citrullination in histone H2B and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H3 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of citrullination in histone H3 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H4 in pregnant women with normal pregnancies
Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry will be used to detect the presence or not of citrullination in histone H4 and recorded as YES/NO.
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H2A in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H2B in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H3 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H4 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Intensity of acetylation in histone H2A in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of acetylation in histone H2B in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of acetylation in histone H3 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of acetylation in histone H4 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H2A in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H2B in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H3 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H4 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H2A in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H2B in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H3 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H4 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H2A in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H2B in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H3 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H4 in pregnant women with normal pregnancies
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia
Mass spectrometry, quantitative
Time frame: At pregnancy term (max 41 weeks gestation)
Presence of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 of pregnancy
Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: After 34 weeks of pregnancy
Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
YES/NO
Time frame: Before 34 weeks of pregnancy
Presence of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
YES/NO
Time frame: 34 to 41 weeks of pregnancy
Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of methylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of methylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of methylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of methylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of acetylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of acetylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of acetylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of acetylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of phosphorylation in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of phosphorylation in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of phosphorylation in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of phosphorylation in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of ubiquitination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of ubiquitination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 of pregnancy
Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of ubiquitination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of ubiquitination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of citrullination in histone H2A in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of citrullination in histone H2B in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of citrullination in histone H3 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia before 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of citrullination in histone H4 in pregnant women developing pre-eclampsia after 34 weeks of pregnancy
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy
Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia early on will be recorded as YES/NO.
Time frame: Before 34 weeks of pregnancy
Modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
The presence of methylation, acetylation, phosphorylation, ubiquitination and citrullination in each histone in women developing pre-eclampsia later on will be recorded as YES/NO.
Time frame: 34 to 41 weeks of pregnancy
Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia early on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
Mass spectrometry, quantitative
Time frame: Before 34 weeks of pregnancy
Intensity of modifications in histones H2A, H2B, H3 and H4 in women developing pre-eclampsia later on compared with modifications in histones H2A, H2B, H3 and H4 in women with normal pregnancies.
Mass spectrometry, quantitative
Time frame: 34 to 41 weeks of pregnancy